Biocon sees a sweet spot with its affordable insulin in US
Posted by
www.biotecnika.org
The biotech firm is also planning to provide its rh-insulin to middle-
and low-income countries at less than 10 cents a day. Biocon Biologics
is chasing a revenue target of $1 billion in financial year 2021-22.
In the previous fiscal year, its revenue had topped $200 million.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-sees-a-sweet-spot-with-its-affordable-insulin-in-us/articleshow/72376960.cms
Subscribe to:
Post Comments (Atom)
Post a Comment